:’
KalVista Pharmaceuticals, Inc. has presented new data on sebetralstat at the Bradykinin Symposium 2024, detailing findings from multiple phases of clinical trials. This article summarizes the key outcomes related to efficacy and safety gathered from phase 2 and phase 3 double-blind, placebo-controlled crossover trials, alongside interim results from the KONFIDENT-S extension trial and real-world data.
KalVista Pharmaceuticals, based in Cambridge, Massachusetts, and Salisbury, England, continues to advance its innovative approach to treating diseases linked to bradykinin dysregulation. The company recently showcased significant data concerning its investigational drug, sebetralstat, at the Bradykinin Symposium held in Berlin, Germany, on September 5-6, 2024.
Methods:’
Data presented included results from both phase 2 and phase 3 double-blind, placebo-controlled crossover clinical trials assessing the safety and efficacy of sebetralstat. Additionally, interim data from KONFIDENT-S, an ongoing phase 3 open-label extension trial, and supplemental real-world patient data were shared.
Efficacy Results:’
The analyses demonstrated that sebetralstat effectively reduces the frequency and severity of bradykinin-mediated attacks, reinforcing its potential as a therapeutic option for patients with conditions influenced by excess bradykinin. The double-blind trials provided strong evidence supporting the drug’s action, with statistically significant reductions in attack rates observed in treatment groups compared to placebo.
Safety Profile:’
Regarding safety, sebetralstat was reported to be well-tolerated among study participants, with adverse events being consistent with those observed in previous studies. The data underscored the importance of continued safety monitoring, particularly as patient populations expand in the context of real-world applications.
Interim Data from KONFIDENT-S Trial:’
As part of the presentation at the symposium, interim results from the KONFIDENT-S trial highlighted additional insights into long-term safety and efficacy, aiding the understanding of sebetralstat’s potential in a broader patient population. Participants showed sustained improvements in health-related quality of life and frequency of attacks over the study duration.
Real-World Evidence:’
KalVista also presented real-world patient data, further supporting the clinical trial findings. This data emphasized the necessity of considering real-world scenarios in the assessment of treatment effectiveness and patient outcomes.
Conclusion:’
The newly presented data at the Bradykinin Symposium 2024 confirms the promising efficacy and safety of sebetralstat, solidifying its potential role in managing bradykinin-related disorders. As clinical experience and real-world evidence continue to accumulate, KalVista Pharmaceuticals is positioned to potentially offer significant therapeutic advancements for patients affected by these conditions.
Keywords:’ Sebetralstat, KalVista Pharmaceuticals, Bradykinin Symposium 2024, efficacy, safety, clinical trials, real-world data, phase 2, phase 3.
Comments